MarketCap
Facebook
X
Telegram
Intercept Pharmaceuticals Balance Sheet 2022-2002 | ICPT
Brief overview of Intercept Pharmaceuticals's assets and capital
The comparison uses five available annual reports from the 2018–2022 interval.
The asset base gained +8.7%, from $509.2 million to $553.7 million; average annual growth of 2.1% remained moderate.
Liabilities grew more slowly than assets: -6% versus +8.7%. Expansion relied more on equity, improving funding quality.
The equity ratio equals 16.8%, with a starting level of 3.8%. Stable cash flow is important under this structure.
The net-debt-to-equity ratio reached 1.85x. High leverage materially limits financial flexibility.
The cash reserve occupies 9.1% of the balance sheet, previously 8.5%. It is one marker of short-term resilience.
The balance sheet includes a negative accumulated result of -$2.1 billion. It should be assessed alongside historical profits and capital distributions.
Conclusion
Intercept Pharmaceuticals has limited balance sheet resilience and depends heavily on cash generation and refinancing capacity.
Annual Balance Sheet Intercept Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
173 M | 458 M | 510 M | 468 M | 328 M | 286 M | 298 M | -32.7 M | -20 M | -13.4 M | -45.5 M | -17.6 M | - | - | - | - | - |
Long Term Debt |
223 M | 540 M | 561 M | 532 M | 371 M | 356 M | 341 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 3.04 M | 7.25 M | 6.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 541 M | 376 M | 364 M | 346 M | 6.24 M | 8.02 M | 59 M | 33.3 M | 18 M | - | - | - | - | - |
Total Current Liabilities |
230 M | 168 M | 179 M | 162 M | 114 M | 104 M | 78.5 M | 47.4 M | 15.2 M | 8.88 M | 13 M | 4.03 M | - | - | - | - | - |
Total Liabilities |
461 M | 711 M | 747 M | 703 M | 490 M | 468 M | 424 M | 53.6 M | 23.3 M | 67.9 M | 46.3 M | 22 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 1.62 M | 1.78 M | 5.69 M | 1.78 M | 1.78 M | 1.62 M | 1.62 M | 2.45 M | - | - | - | - | - |
Retained Earnings |
-2.14 B | -2.49 B | -2.4 B | -2.12 B | -1.78 B | -1.47 B | -1.11 B | -696 M | -469 M | -186 M | -118 M | -74.5 M | - | - | - | - | - |
Total Assets |
554 M | 527 M | 580 M | 755 M | 509 M | 484 M | 739 M | 656 M | 254 M | 150 M | 112 M | 19.5 M | - | - | - | - | - |
Cash and Cash Equivalents |
50.5 M | 84.7 M | 58.2 M | 70.1 M | 43.2 M | 70 M | 43.7 M | 32.7 M | 20 M | 13.4 M | 45.5 M | 17.7 M | 15.4 M | 4.43 M | - | - | - |
Book Value |
93.1 M | -184 M | -167 M | 51.6 M | 19.1 M | 16.4 M | 315 M | 602 M | 231 M | 82.4 M | 65.9 M | -2.56 M | - | - | - | - | - |
Total Shareholders Equity |
93.1 M | -184 M | -167 M | 51.6 M | 19.1 M | 16.4 M | 315 M | 602 M | 231 M | 82.4 M | 65.9 M | -2.56 M | 8.32 M | 2.12 M | 17.7 M | 6.49 M | - |
All numbers in USD currency
Quarterly Balance Sheet Intercept Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
224 M | 224 M | 223 M | 223 M | 223 M | 714 M | 717 M | 540 M | 530 M | 576 M | 568 M | 561 M | 553 M | 546 M | 539 M | 532 M | 525 M | 545 M | 375 M | 371 M | 367 M | 363 M | 359 M | 356 M | 352 M | 348 M | 345 M | 341 M | 338 M | 341 M | 341 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
321 M | 417 M | 437 M | 461 M | 452 M | 868 M | 875 M | 711 M | 679 M | 726 M | 720 M | 747 M | 722 M | 716 M | 697 M | 703 M | 671 M | 678 M | 493 M | 490 M | 461 M | 458 M | 446 M | 468 M | 449 M | 446 M | 428 M | 424 M | 397 M | 108 M | 105 M | 53.6 M | 38.9 M | 30.9 M | 25.7 M | 23.3 M | 25 M | 20.8 M | 296 M | 67.9 M | 67.9 M | 47.6 M | 45.4 M | 46.3 M | 22.9 M | 46.3 M | 46.3 M | 22 M | 22 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.22 M | 1.62 M | 2.72 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 1.78 M | 1.78 M | 6.84 M | 6.02 M | 5.69 M | 3.94 M | 4.46 M | 1.78 M | 1.78 M | 1.78 M | 1.78 M | 1.78 M | 1.78 M | 1.78 M | 1.78 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 2.45 M | 2.45 M | - | - |
Retained Earnings |
-2.18 B | -2.17 B | -2.17 B | -2.14 B | -2.12 B | -2.38 B | -2.38 B | -2.49 B | -2.45 B | -2.45 B | -2.44 B | -2.4 B | -2.35 B | -2.28 B | -2.22 B | -2.12 B | -2.03 B | -1.94 B | -1.87 B | -1.78 B | -1.69 B | -1.63 B | -1.55 B | -1.47 B | -1.36 B | -1.29 B | -1.2 B | -1.11 B | -988 M | -900 M | -822 M | -696 M | -607 M | -556 M | -509 M | -469 M | -469 M | -399 M | -469 M | -186 M | - | -186 M | - | - | - | - | - | - | - | - | - |
Total Assets |
393 M | 485 M | 504 M | 554 M | 559 M | 499 M | 503 M | 527 M | 523 M | 523 M | 520 M | 580 M | 591 M | 637 M | 662 M | 755 M | 802 M | 853 M | 438 M | 509 M | 557 M | 605 M | 394 M | 484 M | 560 M | 616 M | 668 M | 739 M | 812 M | 524 M | 593 M | 656 M | 717 M | 754 M | 422 M | 254 M | 286 M | 311 M | 142 M | 150 M | 159 M | 164 M | 106 M | 112 M | 38.6 M | 112 M | 112 M | 19.5 M | 19.5 M | - | - |
Cash and Cash Equivalents |
103 M | 136 M | 61.4 M | 50.5 M | 113 M | 58 M | 48.3 M | 84.7 M | 68.3 M | 146 M | 92.9 M | 58.2 M | 45.3 M | 50.8 M | 41.4 M | 70.1 M | 63.4 M | 93.5 M | 54.7 M | 43.2 M | 59.4 M | 77.7 M | 48.9 M | 70 M | 120 M | 62 M | 67 M | 43.7 M | 105 M | 51.7 M | 49.2 M | 32.7 M | 72.4 M | 88.3 M | 104 M | 20 M | 18.1 M | 45 M | 11.2 M | 13.4 M | 33.5 M | 52.1 M | 31.7 M | 45.5 M | 36 M | 45.5 M | 45.5 M | 17.7 M | 17.7 M | - | - |
Book Value |
71.8 M | 67.5 M | 67.2 M | 93.1 M | 108 M | -370 M | -372 M | -184 M | -156 M | -203 M | -200 M | -167 M | -130 M | -78.8 M | -34.7 M | 51.6 M | 131 M | 175 M | -55 M | 19.1 M | 95.8 M | 147 M | -52.3 M | 16.4 M | 112 M | 170 M | 240 M | 315 M | 415 M | 417 M | 488 M | 602 M | 678 M | 723 M | 396 M | 231 M | 261 M | 290 M | -154 M | 82.4 M | 91 M | 116 M | 60.8 M | 65.9 M | 15.6 M | 65.9 M | 65.9 M | -2.56 M | -2.56 M | - | - |
Total Shareholders Equity |
71.8 M | 67.5 M | 67.2 M | 93.1 M | 108 M | -370 M | -372 M | -184 M | -156 M | -203 M | -200 M | -167 M | -130 M | -78.8 M | -34.7 M | 51.6 M | 131 M | 175 M | -55 M | 19.1 M | 95.8 M | 147 M | -52.3 M | 16.4 M | 112 M | 170 M | 240 M | 315 M | 415 M | 417 M | 488 M | 602 M | 678 M | 723 M | 396 M | 231 M | 261 M | 290 M | -154 M | 82.4 M | 91 M | 116 M | 60.8 M | 65.9 M | 15.6 M | 65.9 M | 65.9 M | -2.56 M | -2.56 M | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Intercept Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
